Plasmacytoma - 153 Studies Found
| Completed |
: Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma : Multiple Myeloma and Plasma Cell Neoplasm : 2006-03-21 :
|
| Completed |
: Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant : Multiple Myeloma and Plasma Cell Neoplasm : 2006-02-06 : Drug: bortezomib Dose of Bortezomib* Level 1: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 21 days; Level 2: 1.3 |
| Terminated |
: Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders : Multiple Myeloma and Plasma Cell Neoplasm : 2005-11-22 :
|
| Completed |
: Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma : Multiple Myeloma and Plasma Cell Neoplasm : 2005-11-22 :
|
| Terminated |
: Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma : Multiple Myeloma and Plasma Cell Neoplasm : 2005-09-26 :
|
| Withdrawn |
: Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma :
|
| Withdrawn |
: Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma :
|
| Completed |
: Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma : Multiple Myeloma and Plasma Cell Neoplasm : 2004-06-10 : Drug: bortezomib |
| Completed |
: S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma :
: 2003-07-08 :
|
| Completed |
: Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma : Multiple Myeloma and Plasma Cell Neoplasm : 2003-05-06 : Drug: brostallicin Patients receive brostallicin IV over 1 |